Clomiphene (Clomid) vs Letrozole

Head-to-head evidence comparison — which supplement is right for you?

Quick answer⚠ Combine with care

Clomiphene (Clomid) vs Letrozole: they're closely matched on evidence (4.8 vs 5/10); they're alternatives for fertility support — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.

Too Close to Call

Clomiphene (Clomid) and Letrozole are closely matched across evidence, studies, and safety.

Clomiphene (Clomid)1 win

Letrozole1 win

Which is right for you? Take the 60-second quiz Open in the full comparison tool

Cmp4.8

Clomiphene (Clomid)

Too few graded studiesLimited safety

Let5.0

Letrozole

Too few graded studiesLimited safety

Evidence

Evidence Score

4.8/10

Studies: 359

Meta-analyses: 54

Level: Emerging

Evidence Score

Best5/10

Studies: 99

Meta-analyses: 21

Level: Moderate

Research findings

Verdict

Too few graded studies

Top outcomes

Fertility (ovulation & sperm)Too few graded studies211
PCOS & ovulation inductionToo few graded studies165
Testosterone & male hypogonadismToo few graded studies53

Verdict

Too few graded studies

Top outcomes

Women's healthToo few graded studies67
Ovulation induction & fertilityToo few graded studies32
Testosterone & male hormonesToo few graded studies13

Shared outcomes (3)

Outcomes where both Clomiphene (Clomid) and Letrozole have evidence — compare verdict strength side-by-side.

Women's healthToo few graded studies165Too few graded studies67
Ovulation induction & fertilityToo few graded studies211Too few graded studies32
Testosterone & male hormonesToo few graded studies53Too few graded studies13

Dosage & timing

Recommended Dosage:

Off-label (male) / approved (female) — clinician-directed. For female ovulation induction the approved regimen is 50 mg once daily for 5 days starting early in the cycle, titrated up to 100 mg if needed (the US label does not recommend more than 100 mg a day for 5 days). For off-label male hypogonadism, observational studies used roughly 25-50 mg daily or every other day (25 mg/day is the most common starting dose), titrated to testosterone and LH/FSH response. There is no FDA-approved male dose.

Warnings

Clomiphene is FDA-approved only for FEMALE ovulation induction; male hypogonadism use is OFF-LABEL.
The genuine male claim is mechanistically sound but rests largely on OBSERVATIONAL, surrogate-endpoint data. Clomiphene can raise endogenous testosterone in selected men by increasing gonadotropin signalling. Effects on sperm measures vary, and treatment does not guarantee preserved fertility, conception or live birth. Use requires an individual assessment and monitoring by the treating specialist.
There are NO long-term hard-outcome trials for chronic male use — no cardiovascular, fracture, mood, or mortality data over years.
In its main approved use, the landmark NEJM trial (Legro 2014) showed letrozole produced MORE live births than clomiphene in PCOS.
As the RACEMIC mixture, clomiphene carries the long-lived, weakly estrogenic zuclomiphene (serum ratio ~20:1; urinary detection >4 months) — the trade-off the single-isomer enclomiphene was developed to avoid.
Clomiphene-class SERMs carry visual, mood, and (plausibly) thromboembolic concerns; long-term male safety is uncharacterized.
Use only under medical supervision; this is a hormonal/reproductive prescription compound, not a dietary supplement or a longevity agent.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Clomiphene citrate tablets (racemic — approved for women; off-label in men)

Recommended Dosage:

Indication-specific and clinician-directed. Ovulation induction: 2.5-7.5 mg once daily for 5 days early in the cycle (typically days 3-7). Breast cancer: 2.5 mg once daily continuously. Off-label male use mirrors 2.5 mg once to a few times weekly (NOT daily) titrated to testosterone/estradiol — a prescription drug, not an approved supplement regimen.

Warnings

Prescription aromatase inhibitor — NOT a dietary supplement and NOT a longevity drug.
Strongest evidence is for FEMALE ovulation induction in PCOS, where it beats clomiphene on live births (NEJM RCT + high-certainty Cochrane reviews); also approved for hormone-receptor-positive breast cancer.
Off-label male use raises testosterone and lowers estradiol but showed NO somatic/psychological benefit in a placebo-controlled RCT, and chronic estrogen suppression harms bone and lipids.
In growing boys, mild vertebral-body deformities occurred in 45% of letrozole-treated vs 0% on placebo — use during growth requires spine monitoring.
Teratogenic — must not be taken during an established pregnancy. Use only under medical supervision.

Best Time:

Any time of day

Can take on empty stomach

Best Form:

Oral letrozole 2.5 mg tablet (Femara / generic)

Safety

Limited safetyTie

Drug Interactions:

Exogenous testosterone / anabolic steroids (moderate)
Aromatase inhibitors / other SERMs (e.g. tamoxifen, letrozole) (moderate)
Estrogens (moderate)

Side Effects:

Visual disturbances (blurring, flashes, floaters; rarely hallucinations)Hot flushes / vasomotor symptomsMood changes / irritability

Contraindications:

Pregnancy (clomiphene is contraindicated once pregnancy is established)
Liver disease, undiagnosed abnormal uterine bleeding, or ovarian cysts not due to PCOS (per the approved female label)

Limited safetyTie

Drug Interactions:

Tamoxifen / other estrogen-modulating agents (moderate)
Exogenous estrogen / hormone therapy (moderate)
Exogenous testosterone / anabolic steroids (moderate)

Side Effects:

Hot flashesFatigue / dizzinessArthralgia / musculoskeletal aches

Contraindications:

Pregnancy (teratogenic risk) — used to induce ovulation, but stopped once pregnancy occurs
Premenopausal women for breast-cancer indication without ovarian suppression

Interactions between these two

Combine with care

Overlapping effects on the estrogen/HPG axis; stacking is common in TRT and fertility circles but is not well validated and can produce unpredictable estradiol and lipid effects.

Discuss with your healthcare provider before combining.

Full Interaction Analysis

Shared goals

Fertility supportClomiphene (Clomid)

Clomiphene (Clomid)64/100

Letrozole55/100

What you'll notice

🥚 Induces ovulation (approved female use)positive

Per cycle (5-10 day course)

🧬 Raises endogenous testosterone (off-label male use)positive

Weeks to a few months

👶 Hormone changes in selected menpositive

Within 3-6 months

⚠️ Off-label in men; no long-term outcome datatrade-off

N/A

👶 Ovulation induction (beats clomiphene)positive

Per cycle (days 3-7 dosing)

🧬 Raises testosterone / lowers estradiol (men)neutral

Weeks to months

🦴 Bone & lipid cost of low estrogentrade-off

Months to years

🎗️ Approved breast-cancer therapypositive

Months to years

Key studies

Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis.

Andrology (2022) · Meta analysis · n=1642

Systematic review and meta-analysis of clomiphene citrate for male hypogonadism — 19 studies (4 RCTs, 15 observational), 1,642 patients; 17 studies (1,279 patients) in the meta-analysis

Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.

N Engl J Med (2014) · Rct · n=750

Double-blind, multicenter RCT (NCT00719186) of 750 women with PCOS randomized 1:1 to letrozole vs clomiphene for up to five cycles; primary outcome live birth

Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome.

Cochrane Database Syst Rev (2016) · Systematic review · n=3377

Cochrane systematic review of clomiphene and other antioestrogens for ovulation induction in anovulatory PCOS subfertility

All Clomiphene (Clomid) studies

Letrozole versus clomiphene for infertility in the polycystic ovary syndrome.

The New England journal of medicine (2014) · Rct · n=750

Double-blind multicenter RCT of 750 women with PCOS randomized to letrozole or clomiphene for up to five cycles, primary outcome live birth

Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome.

Cochrane Database of Systematic Reviews (2022) · Meta analysis · n=6522

Cochrane systematic review of 41 RCTs (6522 women); letrozole was used in all trials

Somatic and psychological effects of low-dose aromatase inhibition in men with obesity-related hypogonadotropic hypotestosteronemia.

European journal of endocrinology (2013) · Rct · n=42

Double-blind, placebo-controlled 6-month RCT of letrozole in 42 obese men (BMI >35) with low testosterone, dose-titrated to a target testosterone

All Letrozole studies

Frequently asked questions

Is Clomiphene (Clomid) better than Letrozole?

Both Clomiphene (Clomid) and Letrozole are closely matched — the best choice depends on your specific health goals.

Is Clomiphene (Clomid) or Letrozole better for fertility support?

For fertility support, Clomiphene (Clomid) has a higher relevance score (64 vs 55).

Can I take Clomiphene (Clomid) and Letrozole together?

Overlapping effects on the estrogen/HPG axis; stacking is common in TRT and fertility circles but is not well validated and can produce unpredictable estradiol and lipid effects. Discuss with your healthcare provider before combining. Consult a healthcare provider for personalized advice.

Related comparisons

Folic Acid vs Letrozole Letrozole vs Prenatal Multivitamin Lactoferrin vs Letrozole L. crispatus CTV-05 vs Letrozole

Still deciding between Clomiphene (Clomid) and Letrozole?

The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.

Get your personalised pick Clomiphene (Clomid) details Letrozole details

Warnings

Clomiphene is FDA-approved only for FEMALE ovulation induction; male hypogonadism use is OFF-LABEL.

The genuine male claim is mechanistically sound but rests largely on OBSERVATIONAL, surrogate-endpoint data. Clomiphene can raise endogenous testosterone in selected men by increasing gonadotropin signalling. Effects on sperm measures vary, and treatment does not guarantee preserved fertility, conception or live birth. Use requires an individual assessment and monitoring by the treating specialist.

There are NO long-term hard-outcome trials for chronic male use — no cardiovascular, fracture, mood, or mortality data over years.

In its main approved use, the landmark NEJM trial (Legro 2014) showed letrozole produced MORE live births than clomiphene in PCOS.

As the RACEMIC mixture, clomiphene carries the long-lived, weakly estrogenic zuclomiphene (serum ratio ~20:1; urinary detection >4 months) — the trade-off the single-isomer enclomiphene was developed to avoid.

Clomiphene-class SERMs carry visual, mood, and (plausibly) thromboembolic concerns; long-term male safety is uncharacterized.

Use only under medical supervision; this is a hormonal/reproductive prescription compound, not a dietary supplement or a longevity agent.

Warnings

Prescription aromatase inhibitor — NOT a dietary supplement and NOT a longevity drug.

Strongest evidence is for FEMALE ovulation induction in PCOS, where it beats clomiphene on live births (NEJM RCT + high-certainty Cochrane reviews); also approved for hormone-receptor-positive breast cancer.

Off-label male use raises testosterone and lowers estradiol but showed NO somatic/psychological benefit in a placebo-controlled RCT, and chronic estrogen suppression harms bone and lipids.

In growing boys, mild vertebral-body deformities occurred in 45% of letrozole-treated vs 0% on placebo — use during growth requires spine monitoring.

Teratogenic — must not be taken during an established pregnancy. Use only under medical supervision.

Frequently asked questions

Is Clomiphene (Clomid) better than Letrozole?

Both Clomiphene (Clomid) and Letrozole are closely matched — the best choice depends on your specific health goals.

Is Clomiphene (Clomid) or Letrozole better for fertility support?

For fertility support, Clomiphene (Clomid) has a higher relevance score (64 vs 55).